About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 852839, 13 pages
http://dx.doi.org/10.1155/2013/852839
Review Article

New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches

Department of Clinical Medicine and Surgery, University Hospital and University Federico II, via Pansini 5, 80131 Naples, Italy

Received 18 February 2013; Accepted 14 May 2013

Academic Editor: Athanassios Dellas

Copyright © 2013 P. Rescigno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. GLOBOCAN 2008 v1.2. Cancer Incidence and Mortality Worldwide, IARC CancerBase, no. 10, IARC Press, Lyon, France, 2010, http://globocan.iarc.fr/.
  2. A. P. Heintz, F. Odicino, P. Maisonneuve, et al., “Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer,” International Journal of Gynaecology and Obstetrics, vol. 95, supplement 1, pp. S161–S192, 2006. View at Publisher · View at Google Scholar
  3. N. Colombo, D. Guthrie, S. Chiari et al., “International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer,” Journal of the National Cancer Institute, vol. 95, no. 2, pp. 125–132, 2003. View at Scopus
  4. M. J. Piccart, K. Bertelsen, K. James, et al., “Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results,” Journal of the National Cancer Institute, vol. 92, no. 9, pp. 699–708, 2000. View at Scopus
  5. R. A. Burger, M. F. Brady, M. A. Bookman, et al., “Incorporation of bevacizumab in the primary treatment of ovarian cancer,” The New England Journal of Medicine, vol. 365, pp. 2473–2483, 2011.
  6. T. J. Perren, A. M. Swart, J. Pfisterer, et al., “A phase 3 trial of bevacizumab in ovarian cancer,” The New England Journal of Medicine, vol. 365, no. 26, pp. 2484–2496, 2011. View at Publisher · View at Google Scholar
  7. R. J. Kurman and I.-M. Shih, “Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm,” Human Pathology, vol. 42, no. 7, pp. 918–931, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Prat, “Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features,” Virchows Archiv, vol. 460, no. 3, pp. 237–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. K. R. Lee, F. A. Tavassoli, J. Prat, et al., “Tumours of the ovary and peritoneum: surface epithelial-stromal tumours,” in World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, F. A. Tavassoli and P. Devilee, Eds., chapter 2, pp. 117–145, IARC Press, Lyon, France, 2003.
  10. A. A. Ahmed, D. Etemadmoghadam, J. Temple et al., “Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary,” Journal of Pathology, vol. 221, no. 1, pp. 49–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Senturk, S. Cohen, P. R. Dottino, and J. A. Martignetti, “A critical re-appraisal of BRCA1 methylation studies in ovarian cancer,” Gynecologic Oncology, vol. 119, no. 2, pp. 376–383, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Kurman and I.-M. Shih, “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory,” American Journal of Surgical Pathology, vol. 34, no. 3, pp. 433–443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. J. Piek, P. J. van Diest, R. P. Zweemer et al., “Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer,” Journal of Pathology, vol. 195, no. 4, pp. 451–456, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Chêne, F. Penault-Llorca, G. le Bouëdec et al., “Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk,” International Journal of Gynecological Cancer, vol. 19, no. 1, pp. 65–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. M. J. Piek, R. H. M. Verheijen, P. Kenemans, L. F. Massuger, H. Bulten, and P. J. van Diest, “BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis,” Gynecologic Oncology, vol. 90, no. 2, p. 491, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Callahan, C. P. Crum, F. Medeiros et al., “Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3985–3990, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. D. W. Kindelberger, Y. Lee, A. Miron et al., “Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship,” American Journal of Surgical Pathology, vol. 31, no. 2, pp. 161–169, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. C. Wiegand, S. P. Shah, O. M. Al-Agha, et al., “ARID1A mutations in endometriosis-associated ovarian carcinomas,” The New England Journal of Medicine, vol. 363, no. 16, pp. 1532–1543, 2010. View at Publisher · View at Google Scholar
  19. M. L. Carcangiu, P. Radice, S. Manoukian et al., “Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers,” International Journal of Gynecological Pathology, vol. 23, no. 1, pp. 35–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Medeiros, M. G. Muto, Y. Lee et al., “The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome,” American Journal of Surgical Pathology, vol. 30, no. 2, pp. 230–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Lee, A. Miron, R. Drapkin, et al., “A candidate precursor to serous carcinoma that originates in the distal fallopian tube,” The Journal of Pathology, vol. 211, no. 1, pp. 26–35, 2007. View at Publisher · View at Google Scholar
  22. E. Veras, T.-L. Mao, A. Ayhan et al., “Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases,” American Journal of Surgical Pathology, vol. 33, no. 6, pp. 844–853, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. S. E. Bulun, “Endometriosis,” The New England Journal of Medicine, vol. 360, no. 3, pp. 268–279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. B. T. Hennessy, R. L. Coleman, and M. Markman, “Ovarian cancer,” The Lancet, vol. 374, no. 9698, pp. 1371–1382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. “FIGO annual report, vol. 24,” The Journal of Epidemiology and Biostatistics, vol. 6, pp. 107–138, 2001.
  26. C. B. Gilks, D. N. Ionescu, S. E. Kalloger et al., “Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma,” Human Pathology, vol. 39, no. 8, pp. 1239–1251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Bamias, M. Sotiropoulou, F. Zagouri et al., “Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor,” European Journal of Cancer, vol. 48, no. 10, pp. 1476–1483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Köbel, S. E. Kalloger, P. M. Baker et al., “Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study,” American Journal of Surgical Pathology, vol. 34, no. 7, pp. 984–993, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. R. J. Zaino, M. F. Brady, S. M. Lele, H. Michael, B. Greer, and M. A. Bookman, “Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal,” Cancer, vol. 117, no. 3, pp. 554–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Alexandre, I. Ray-Coquard, F. Selle et al., “Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience,” Annals of Oncology, vol. 21, no. 12, pp. 2377–2381, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. R. J. Zaino, M. F. Brady, S. M. Lele, H. Michael, B. Greer, and M. A. Bookman, “Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study,” Cancer, vol. 117, no. 3, pp. 554–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Ayhan, R. J. Kurman, A. Yemelyanova et al., “Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis,” American Journal of Surgical Pathology, vol. 33, no. 8, pp. 1220–1224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. C. le Page, D. G. Huntsman, D. M. Provencher, and A.-M. Mes-Masson, “Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies,” Cancers, vol. 2, no. 2, pp. 913–954, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Milde-Langosch and S. Riethdorf, “Role of cell-cycle regulatory proteins in gynecological cancer,” Journal of Cellular Physiology, vol. 196, no. 2, pp. 224–244, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. J. A. Green, E. M. Berns, C. Coens et al., “Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865),” European Journal of Cancer, vol. 42, no. 15, pp. 2539–2548, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, pp. 609–615, 2011. View at Publisher · View at Google Scholar
  37. A. Bali, P. M. O'Brien, L. S. Edwards, R. L. Sutherland, N. F. Hacker, and S. M. Henshall, “Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer,” Clinical Cancer Research, vol. 10, no. 15, pp. 5168–5177, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. H. E. Geisler, J. P. Geisler, G. A. Miller, et al., “p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone,” Cancer, vol. 92, no. 4, pp. 781–786, 2001.
  39. A. Schmider-Ross, O. Pirsig, E. Gottschalk, C. Denkert, W. Lichtenegger, and A. Reles, “Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 3, pp. 163–170, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Skirnisdottir and T. Seidal, “Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer,” Cancer Genomic and Proteomics, vol. 10, pp. 27–34, 2013.
  41. E. Verri, P. Guglielmini, M. Puntoni et al., “HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance: clinical study,” Oncology, vol. 68, no. 2-3, pp. 154–161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Hillig, J. Thode, M. F. Breinholt, et al., “Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer,” APMIS, vol. 120, pp. 1000–1007, 2012. View at Publisher · View at Google Scholar
  43. N. Nakayama, K. Nakayama, Y. Shamima et al., “Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer,” Cancer, vol. 116, no. 11, pp. 2621–2634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. A. R. Venkitaraman, “Cancer susceptibility and the functions of BRCA1 and BRCA2,” Cell, vol. 108, no. 2, pp. 171–182, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Chen and G. Parmigiani, “Meta-analysis of BRCA1 and BRCA2 penetrance,” Journal of Clinical Oncology, vol. 25, no. 11, pp. 1329–1333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Antoniou, P. D. P. Pharoah, S. Narod et al., “Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies,” American Journal of Human Genetics, vol. 72, no. 5, pp. 1117–1130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Z. Press, A. de Luca, N. Boyd et al., “Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities,” BMC Cancer, vol. 8, article 17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. B. M. Norquist, R. L. Garcia, K. H. Allison et al., “The molecular pathogenesis of hereditary ovarian carcinoma,” Cancer, vol. 116, no. 22, pp. 5261–5271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. Wang, F. Wang, T. Tang, and C. Guo, “The role of PARP1 in DNA damage response and its application in tumor therapy,” Frontiers of Medicine, vol. 6, no. 2, pp. 156–164, 2012. View at Publisher · View at Google Scholar
  50. M. K. Weil and A. P. Chen, “PARP inhibitor treatment in ovarian and breast cancer,” Current Problems in Cancer, vol. 35, no. 1, pp. 7–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Schubbert, K. Shannon, and G. Bollag, “Hyperactive Ras in developmental disorders and cancer,” Nature Reviews Cancer, vol. 7, no. 4, pp. 295–308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. I. Vereczkey, O. Serester, J. Dobos et al., “Molecular characterization of 103 ovarian serous and mucinous tumors,” Pathology and Oncology Research, vol. 17, no. 3, pp. 551–559, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A. J. Hanrahan, N. Schultz, M. L. Westfal, et al., “Genomic complexity and AKT dependence in serous ovarian cancer,” Cancer Discovery, vol. 2, pp. 56–67, 2012. View at Publisher · View at Google Scholar
  54. S. M. Johnson, H. Grosshans, J. Shingara et al., “RAS is regulated by the let-7 microRNA family,” Cell, vol. 120, no. 5, pp. 635–647, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Caiola, E. Rulli, R. Fruscio, A. Buda, M. Broggini, and M. Marabese, “KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer,” American Journal of Cancer Research, vol. 2, no. 3, pp. 298–308, 2012.
  56. D. A. Levine, F. Bogomolniy, C. J. Yee et al., “Frequent mutation of the PIK3CA gene in ovarian and breast cancers,” Clinical Cancer Research, vol. 11, no. 8, pp. 2875–2878, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. N. T. Ihle, R. Lemos Jr., P. Wipf et al., “Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic ras is a dominant predictor for resistance,” Cancer Research, vol. 69, no. 1, pp. 143–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Di Nicolantonio, S. Arena, J. Tabernero et al., “Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus,” Journal of Clinical Investigation, vol. 120, no. 8, pp. 2858–2866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Janku, J. J. Wheler, S. N. Westin et al., “PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations,” Journal of Clinical Oncology, vol. 30, no. 8, pp. 777–782, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. K.-K. Wong, Y. T. M. Tsang, M. T. Deavers et al., “BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas,” American Journal of Pathology, vol. 177, no. 4, pp. 1611–1617, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. D. M. Gershenson, C. C. Sun, D. Bodurka et al., “Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant,” Gynecologic Oncology, vol. 114, no. 1, pp. 48–52, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. E. W. Joseph, C. A. Pratilas, P. I. Poulikakos et al., “The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14903–14908, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Farley, W. E. Brady, V. Vathipadiekal, et al., “Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study,” The Lancet Oncology, vol. 14, no. 2, pp. 134–140, 2013. View at Publisher · View at Google Scholar
  64. R. N. Grisham, G. Iyer, K. Garg, et al., “BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer,” Cancer, vol. 119, no. 3, pp. 548–554, 2013. View at Publisher · View at Google Scholar
  65. D. Cheng, B. Liang, and Y. Li, “Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer,” PLoS One, vol. 8, no. 2, Article ID e55309, 2013.
  66. J. B. Trimbos, M. Parmar, I. Vergote et al., “International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 2, pp. 105–112, 2003. View at Scopus
  67. W. P. McGuire, W. J. Hoskins, M. F. Brady, et al., “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer,” The New England Journal of Medicine, vol. 334, pp. 1–6, 1996. View at Publisher · View at Google Scholar
  68. F. M. Muggia, P. S. Braly, M. F. Brady et al., “Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 106–115, 2000. View at Scopus
  69. L. M. Ellis and D. J. Hicklin, “VEGF-targeted therapy: mechanisms of anti-tumour activity,” Nature Reviews Cancer, vol. 8, no. 8, pp. 579–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. M. R. Raspollini, F. Castiglione, F. Garbini et al., “Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma,” International Journal of Surgical Pathology, vol. 13, no. 2, pp. 135–142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Takano, Y. Kikuchi, N. Yaegashi et al., “Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging,” British Journal of Cancer, vol. 94, no. 10, pp. 1369–1374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. A. du Bois, H. J. Luck, W. Meier, et al., “A randomized cinic trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer,” The Journal of the National Cancer Institute, vol. 95, pp. 1320–1329, 2003.
  73. M. Köbel, S. E. Kalloger, J. Carrick et al., “A limited Panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of theovary,” American Journal of Surgical Pathology, vol. 33, no. 1, pp. 14–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. J. A. Lederman, C. Marth, M. S. Carey, et al., “Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer,” International Journal of Gynecological Cancer, vol. 21, no. 4, pp. 763–770, 2011. View at Publisher · View at Google Scholar
  75. W. D. Foulkes, “BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis,” Familial Cancer, vol. 5, no. 2, pp. 135–142, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. K. L. Bolton, G. Chenevix-Trench, P. D. Pharoah, et al., “Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer,” The Journal of the American Medical Association, vol. 307, no. 4, pp. 382–390, 2012. View at Publisher · View at Google Scholar
  77. D. Yang, S. Khan, Y. Sun et al., “Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer,” The Journal of the American Medical Association, vol. 306, no. 14, pp. 1557–1565, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Farmer, H. McCabe, C. J. Lord et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy,” Nature, vol. 434, no. 7035, pp. 917–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. P. C. Fong, D. S. Boss, T. A. Yap et al., “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers,” The New England Journal of Medicine, vol. 361, no. 2, pp. 123–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Ashworth, “A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3785–3790, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. W. G. Kaelin Jr., “The concept of synthetic lethality in the context of anticancer therapy,” Nature Reviews Cancer, vol. 5, no. 9, pp. 689–698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. M. W. Audeh, J. Carmichael, R. T. Penson et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial,” The Lancet, vol. 376, no. 9737, pp. 245–251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. T. A. Yap, S. K. Sandhu, C. P. Carden, and J. S. de Bono, “Poly (ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic,” CA: A Cancer Journal for Clinicians, vol. 61, no. 1, pp. 31–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. J. Ang, T. A. Yap, P. C. Fong, et al., “Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, 2010, abstract no. 5041.
  85. K. Kristjansdottir and D. Dizon, “HER-dimerization inhibitors: evaluating pertuzumab in women's cancers,” Expert Opinion on Biological Therapy, vol. 10, no. 2, pp. 243–250, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz, “Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group,” Journal of Clinical Oncology, vol. 21, no. 2, pp. 283–290, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Heublein, T. Vrekoussis, D. Mayr, et al., “Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR),” Journal of Ovarian Research, vol. 6, no. 1, article 6, 2013. View at Publisher · View at Google Scholar
  88. G. F. Schwartz, K. S. Hughes, H. T. Lynch et al., “Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007,” Cancer, vol. 113, no. 10, pp. 2627–2637, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. S. M. Domchek, T. M. Friebel, C. F. Singer et al., “Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality,” The Journal of the American Medical Association, vol. 304, no. 9, pp. 967–975, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. L. T. Shuster, B. S. Gostout, B. R. Grossardt, and W. A. Rocca, “Prophylactic oophorectomy in premenopausal women and long-term health,” Menopause International, vol. 14, no. 3, pp. 111–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. N. Turner, A. Tutt, and A. Ashworth, “Hallmarks of ‘BRCAness’ in sporadic cancers,” Nature Reviews Cancer, vol. 4, no. 10, pp. 814–819, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. February 2013, http://www.cancer.gov/clinicaltrials.